While the study was limited to in vitro demonstration of EZH2 inhibition, future studies will need to account for heterogeneity in cell populations, as well as investigating the ability to reverse hyperglycaemia in pre-clinical models whilst further characterizing the responsive-regenerative cells. Here, EZH2 is linked to Hyperglycemia.